Sebastiano Collino

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 13 (Patent Applications = 21)

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 53(Granted Patents)

Company Filing History:

Societe Des Produits Nestle S.a.

patents

Years Active: 2015-2020

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10648991 - Biomarkers for epicardial adipose tissue (2020-05-12),

2. 10094819 - Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity (2018-10-09),

3. 10036740 - Trimethylamine as a biomarker of prebiotic efficacy for weight gain prevention (2018-07-31),

4. 9817003 - 9-oxo-HODE as a biomarker for healthy aging (2017-11-14),

5. 9523671 - Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention (2016-12-20),

6. 9518975 - Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention (2016-12-13),

7. 9500660 - Isovalerylglycine as biomarker for the predispositon for weight gain and obesity (2016-11-22),

8. 9410963 - Hexanoylglycine as biomarker for the predisposition for weight gain and obesity (2016-08-09),

9. 9341615 - PC-O 40:1 as a biomarker for healthy aging (2016-05-17),

10. 9322821 - P-cresol sulphate as a biomarker for healthy aging (2016-04-26),

11. 9301941 - Methods for preventing or treating sarcopenia and muscle atrophy in animals (2016-04-05),

12. 9201064 - Phenylacetylglutamine as a biomarker for healthy aging (2015-12-01),

Title: The Innovative Contributions of Sebastiano Collino in Biomarker Research

Introduction: Sebastiano Collino, an accomplished inventor based in Lausanne, Switzerland, has made remarkable strides in the field of biomarker research. With a compelling portfolio of 12 patents, his work primarily focuses on advancements in health and nutrition, offering innovative methods for predicting obesity and analyzing adipose tissue.

Latest Patents: Among his latest contributions are two significant patents. The first is related to biomarkers for epicardial adipose tissue (EAT). This method enables the prediction of EAT levels in a subject by determining specific lipid biomarkers in a sample and comparing these levels to reference values, thus providing insights into adipose fat levels.

The second patent centers on trimethylamine-N-oxide as a biomarker for predisposition to weight gain and obesity. This invention features a method for diagnosing the likelihood of an individual to resist or be susceptible to diet-induced weight gain, highlighting the critical role of this biomarker in nutrition and health.

Career Highlights: Collino's career showcases his dedication to research and innovation. He has significantly contributed to the development of health-related biomarkers and their implications for weight management and adipose tissue health. His work not only advances scientific understanding but also paves the way for potential commercial applications.

Collaborations: Throughout his career, Sebastiano has collaborated with esteemed individuals, including Francois-Pierre Martin and Ivan Montoliu Roura. These partnerships have facilitated the exchange of ideas and fostered advancements in biomarker research.

Conclusion: Sebastiano Collino stands out as a pivotal figure in the realm of biomarker innovations, demonstrating a profound commitment to improving health outcomes through his research. His patents not only signify personal achievement but also hold promise for significant contributions to various health-related fields in the future.

This text is generated by artificial intelligence and may not be accurate.